Health risks of counterfeit pharmaceuticals

被引:22
作者
ten Ham, M [1 ]
机构
[1] Minist Publ Hlth Welf & Sport, Dept Pharmaceut & Med Technol, The Hague, Netherlands
关键词
Drug Regulatory Authority; Counterfeit Drug; Counterfeit Product; Public Health Point; Counterfeit Medicine;
D O I
10.2165/00002018-200326140-00001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pharmaceutical products are not exempt from the practice of counterfeiting. In recent years, many reports have become available demonstrating the presence of fake medicines on the market. Several studies have demonstrated that they are quite often of bad quality. It is estimated that 5% of all world trade in branded goods is counterfeit, leading to huge financial losses for the pharmaceutical industry. But much more important, from a public health point of view, is that history has shown that such products may lead to a great health risk. The essence of counterfeit products and the reason they are so dangerous is the complete absence of quality control, since they are often indistinguishable from the genuine product. The existence of counterfeit drugs has long been ignored both by the pharmaceutical industry and by drug regulatory authorities. At present initiatives are being taken, nationally and internationally, to curb counterfeiting. It is now realised that a strong regulatory agency is essential, but the initiatives can only be successful if all parties concerned actively co-operate.
引用
收藏
页码:991 / 997
页数:7
相关论文
共 16 条
[1]  
BANEERJEE A, 1995, ASIAN 0405
[2]  
BRUNETON C, 1997, RES MED DEV
[3]  
*CDA FDA, 1997, DIETH GLYC CONT PREV
[4]  
CUFF R, 1996, DRUG INF J, V29, P633
[5]  
LEPARC M, 2002, PROTECTING MED PHARM
[6]  
POOLE D, 1989, DRUG DISTRIBUTION FA
[7]  
*PROD SUR CTR, RES CTR IND GOV AG I
[8]  
*SCRIP, 1999, PAK TACKL COUNT
[9]  
TENHAM M, 1992, ADVERSE DRUG REACT T, V11, P59
[10]  
*WHO, 1997, COUNT DRUGS REP INT